Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia

Abstract Background A Phase II proof of concept (POC) randomized clinical trial was conducted to evaluate the effects of rasagiline, a monoamine oxidase B (MAO‐B) inhibitor approved for Parkinson disease, in mild to moderate Alzheimer's disease (AD). The primary objective was to determine if 1 ...

Full description

Bibliographic Details
Main Authors: Dawn C. Matthews, Aaron Ritter, Ronald G. Thomas, Randolph D. Andrews, Ana S. Lukic, Carolyn Revta, Jefferson W. Kinney, Babak Tousi, James B. Leverenz, Howard Fillit, Kate Zhong, Howard H. Feldman, Jeffrey Cummings
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Alzheimer's disease
dopamine
FDG‐PET
flortaucipir
glucose metabolism
MAO‐B
Online Access:https://doi.org/10.1002/trc2.12106

Internet

https://doi.org/10.1002/trc2.12106

Similar Items